- Shares Triple on Deal News: Co-Diagnostics, Inc. (NASDAQ: CODX) stock surged by over 200% on October 27, 2025, after the company announced a major joint venture in Saudi Arabia [1]. The stock jumped from around $0.35 late last week to close about $1.07 on Monday [2] [3], with an intraday high of $1.26.
- Middle East Joint Venture: Co-Diagnostics has signed a definitive agreement with Saudi-based Arabian Eagle Manufacturing to form CoMira Diagnostics, a joint venture that will manufacture and distribute Co-Dx’s PCR testing platform across Saudi Arabia and 18 other Middle East/North African countries [4] [5]. CEO Dwight Egan said the deal “expands the reach of our exciting healthcare innovations into a region with a large and growing market for medical devices and point-of-care diagnostics” [6].
- Retail Trading Frenzy: The stunning rally was accompanied by extremely heavy trading volume (over 100 million shares) and frenzied retail investor activity. Social platforms saw sentiment flip to “extremely bullish” from bearish as chatter spiked to very high levels following the news [7].
- Analysts See Upside – With Caution: Prior to the spike, Wall Street had a bullish outlook on CODX. D. Boral Capital recently reaffirmed a Buy rating with a $3.00 price target [8], and the consensus target was around $2.00 per share [9] – far above last week’s prices. This implies potential further upside, though one analyst (H.C. Wainwright) had a more cautious $1.00 target [10] (now essentially met by the current price).
- Broader Context: Co-Diagnostics is a Utah-based molecular diagnostics company known for its patented PCR testing technology [11]. It saw booming demand during early COVID-19 but revenues have since plummeted – the company reported only $200,000 in Q2 2025 revenue (down from $2.7 million a year prior) [12]. The firm is investing in an upcoming at-home/point-of-care PCR platform (not yet FDA-approved [13]) and recently raised $3.8 million via a stock offering at $0.40/share to fund development and operations [14].
Stock Skyrockets on Saudi Arabia Deal Announcement
Co-Diagnostics’ stock price erupted on Monday after the company unveiled a strategic joint venture in the Middle East. Shares of the small-cap diagnostics firm opened around $0.59 and quickly soared, at one point up 133% to about $0.82 by mid-morning [15]. The surge only intensified as trading progressed – by late morning the stock was up 148% and still climbing, prompting a wave of retail trader excitement online [16]. CODX ultimately closed at $1.07, marking a stunning +206% one-day gain [17]. For context, the stock had ended the prior trading day at roughly $0.35 [18], and was down over 70% in the past year before this week’s news [19].
Volume and retail interest exploded alongside the price. More than 100 million CODX shares changed hands on Oct. 27 – an enormous turnover compared to its typical volume. On Stocktwits and other forums, Co-Diagnostics suddenly became a hot ticker, with sentiment indicators shifting from bearish to “extremely bullish” as traders piled in [20]. The dramatic move put CODX among the day’s top gainers on Nasdaq, alongside a few other small-cap names that saw outsized moves. Such volatility is not unprecedented for micro-cap biotech stocks, but the magnitude (+200% in one day) is exceptional and reflects a convergence of positive news and speculative fervor.
Market commentators attributed the spike primarily to the Saudi joint venture announcement, which substantially expands Co-Dx’s market opportunity (see next section). Some observers also noted the backdrop of a buoyant broader market – U.S. indices were rallying on the day – which may have further fueled risk appetite. “Shares of Co-Diagnostics got a boost, surging 133%… after the company signed a definitive agreement with Arabian Eagle [for a Middle East JV],” Benzinga reported in its market recap [21]. In other words, investors reacted very favorably to the prospect of Co-Diagnostics tapping into a large new region with a local partner.
Inside the Middle East Joint Venture: “CoMira Diagnostics”
The catalyst for CODX’s explosion was news of a landmark partnership in Saudi Arabia. In a press release Monday, Co-Diagnostics announced it has entered a definitive agreement with Arabian Eagle Manufacturing, a Riyadh-based company, to form a joint venture called CoMira Diagnostics [22]. CoMira will be based in Saudi Arabia and will research, develop, manufacture, and commercialize Co-Diagnostics’ molecular testing technologies – including its upcoming Co-Dx PCR point-of-care platform – across the Kingdom and 18 other countries in the Middle East and North Africa (MENA) [23] [24].
This is a major strategic move for Co-Dx. The Middle Eastern market represents a significant growth opportunity, and localizing production there could accelerate adoption of the company’s tests. “We are pleased to announce this agreement… as we expand the reach of our exciting healthcare innovations into a region with a large and growing market for medical devices and point-of-care diagnostics,” said Co-Diagnostics CEO Dwight Egan, highlighting the deal’s importance [25]. The company noted that the venture aligns with Saudi Arabia’s Vision 2030 initiative by promoting technology localization and healthcare innovation [26] [27]. Initially targeting Saudi Food & Drug Authority approval, CoMira aims to leverage Saudi as a springboard into neighboring MENA markets [28].
Under the agreement, Co-Diagnostics will license its PCR testing platform and intellectual property to CoMira on an exclusive basis for the region [29]. The Saudi partner, Arabian Eagle, will provide on-the-ground capabilities – handling local manufacturing setup, regulatory approvals in each country, distribution logistics, and customer support [30]. Arabian Eagle’s principals previously served as Co-Dx’s primary distributors in the Middle East, making Saudi Arabia one of Co-Diagnostics’ largest international markets for its tests to date [31]. This existing relationship likely paved the way for the new venture. “Arabian Eagle… brings regional regulatory expertise, logistics capabilities, and local operational support, while Co-Diagnostics provides the core technology,” noted an AsiaNet News report on the deal [32]. The partnership will enable local production of Co-Dx’s upcoming PCR devices and test kits, which is expected to lower costs and improve turnaround times for healthcare providers in the region [33].
It’s worth noting that this JV had been in the works for some time. Co-Diagnostics signed a strategic Memorandum of Understanding (MOU) with a regional partner in Saudi Arabia back in September 2025 [34], foreshadowing Monday’s definitive agreement. The formal launch of CoMira Diagnostics suggests those plans have now solidified. Timing is also notable – the announcement coincided with the Global Health Exhibition 2025 in Riyadh (Oct. 27–30), which Co-Dx’s executive team attended to showcase its technology [35]. It appears the company is using that high-profile event (as well as a recent Maxim investor conference in NYC) to maximize visibility for its international expansion efforts [36].
For Co-Diagnostics, the upside of CoMira could be significant if execution goes well. The JV opens access to markets like Saudi Arabia, UAE, Egypt, Turkey, and more – a combined population well into the hundreds of millions. Many countries in the region are investing in healthcare infrastructure and diagnostics, creating demand for advanced testing solutions. Co-Dx’s flagship product in development is a portable PCR testing platform (with versions for professional point-of-care use and at-home use) aimed at delivering rapid, accurate molecular test results for diseases like COVID-19, tuberculosis, HPV, and others. This platform is still pending regulatory approval (including FDA review in the U.S.) and not yet commercially available [37]. But CoMira’s plan is to manufacture and roll it out across MENA as soon as approvals are secured. Both partners believe that getting Saudi FDA clearance first will streamline entry into other MENA markets given regulatory harmonization in the region [38].
In sum, the CoMira venture provides validation of Co-Diagnostics’ technology on a global stage and could eventually translate into a new revenue stream from overseas. That prospect clearly electrified investors. However, it’s important to remember that the partnership is just beginning – the JV will need to navigate regulatory hurdles and ramp up production before those Middle East sales materialize. Still, Monday’s news is a strong vote of confidence and a tangible step toward monetizing Co-Dx’s innovations abroad.
Market & Expert Reactions: Why Some See More Room to Run
The extreme rally in CODX has naturally raised the question: Is the stock now overextended, or do experts think this is the start of a sustained turnaround? Financial analysts covering Co-Diagnostics generally struck an optimistic tone even before the Saudi deal, and some are reiterating their bullish outlook in its wake.
Notably, D. Boral Capital – which appears to be the company’s most vocal bull on Wall Street – maintained its “Buy” rating on CODX on October 16, 2025 and set a $3.00 per share price target [39]. Analyst Jason Kolbert of D. Boral Capital has argued that Co-Diagnostics’ technology and pipeline merit a significantly higher valuation. A $3 target represents almost a 755% premium to the ~$0.35 price CODX traded at prior to the JV news [40] [41]. Even after the huge one-day jump, the stock (around $1.07) is still only roughly one-third of that ambitious target.
Overall, among the two or three analysts who officially cover CODX, the consensus price objective was around $2.00before the news [42]. For example, Benzinga reports that across the latest analyst ratings, the high target was $3.00 and the low was $1.00, averaging out near $2 [43]. This suggests that, in analysts’ view, Co-Diagnostics was undervalued in the 30-cent range – essentially pricing in a very pessimistic scenario. The stock’s surge into the $1+ territory has now corrected some of that disconnect. At roughly $1.07, CODX is within the lower end of analysts’ target range but still below the mean forecast. If the Saudi partnership and other growth initiatives pan out, bulls argue there could be further upside toward that $2-$3 zone.
Longer-term forecasts also reflect high hopes. Prior to D. Boral trimming its target (it had been $10 earlier this year), the average one-year price target stood at about $2.04/share – a nearly 483% increase from last week’s price [44]. And according to data compiled by TickerNerd, some analysts even projected the stock could reach $3 or higher by 2026, assuming successful execution [45]. In short, the professional opinion has leaned positive on Co-Dx’s prospects, though the company’s tiny size and volatile fortunes meant few institutional investors paid attention until now.
That said, not everyone is fully on board the hype. HC Wainwright & Co. has kept a more neutral stance, with analyst Yi Chen maintaining a Hold rating and a price target in the $1.00–$1.50 range in recent quarters [46]. That cautious view underscores the risks and uncertainties still surrounding Co-Diagnostics. The company is currently losing money each quarter and needs to significantly scale up product sales to justify a higher valuation. Until the new PCR platform secures approvals and gains commercial traction, revenue may remain minimal. From this perspective, Monday’s price jump could be ahead of fundamentals in the near term. Some traders on stock forums even speculated whether the rally might attract profit-taking or short-seller attention given its magnitude.
For now, however, the momentum is clearly with the bulls. Co-Diagnostics just got a jolt of market confidence (and publicity) that could open doors – for example, the company might seize this chance to raise additional capital at higher prices if needed, or simply enjoy a stronger negotiating hand in partnership talks. The stock’s surge also puts CODX on the radar of many investors who would have overlooked it before. “Co-Diagnostics… +133% after signing a Middle East partnership,” noted TechStock²’s market coverage, highlighting CODX among the day’s big movers [47]. Indeed, appearing on Google Finance’s trending ticker list with a +259% tag (as it did Monday) can itself draw in momentum players [48]. The key for Co-Dx will be converting this excitement into lasting shareholder value by executing on its growth strategy.
Company Outlook: Promising Tech, Slim Revenues, New Catalysts Ahead
Stepping back, Co-Diagnostics is a classic high-risk, high-reward story. The company made a name for itself during the COVID-19 pandemic when demand for its PCR test kits drove a surge in revenue and stock price. However, as the pandemic waned, Co-Dx’s sales collapsed – dropping from $5+ million per quarter in 2021 to only $0.2 million in the most recent quarter (Q2 2025) [49]. The latest earnings (reported August 14) showed an EPS loss of -$0.23, which actually beat analyst expectations by a wide margin [50] (helped by cost-cutting), but revenue was a tiny fraction of what it once was. This highlights the company’s challenge: it needs new products and markets to reignite growth now that COVID testing is no longer a cash cow.
On the innovation front, Co-Diagnostics has been developing its next-generation platform, often described as an at-home or point-of-care PCR testing device. This platform – comprising the Co-Dx PCR Home and Pro instruments plus a mobile app – aims to allow rapid, lab-quality PCR diagnostics in decentralized settings (e.g. clinics, pharmacies, or even patients’ homes). Importantly, it is not yet approved for sale; Co-Dx has multiple tests for the device in the pipeline and hopes to begin clinical evaluations by late 2025 [51]. Among the initial assays being prepared are a tuberculosis test, an 8-strain HPV test, and a respiratory panel, according to the company [52]. Co-Diagnostics has cautioned that the entire platform (device and assays) is under review by the FDA and other regulators [53]. So while the technology is exciting – potentially enabling faster, more accessible PCR diagnostics – the timeline for commercialization depends on regulatory clearance. Any positive news on that front (for example, a successful trial or a limited authorization) would be a major catalyst for the stock in coming months.
The newly announced CoMira joint venture should be seen in this context. It effectively gives Co-Dx a partner to manufacture and distribute the PCR platform in the MENA region once the product is ready [54]. Co-Dx has a similar model in India, where it operates a JV named CoSara Diagnostics Pvt Ltd to localize its tests for the Indian market [55]. By replicating this strategy in the Middle East, Co-Diagnostics is trying to position itself globally for the next phase of growth. The company’s leadership has been actively reaching out – from presenting at the Maxim Growth Summit in New York [56] to showcasing at the Riyadh health exhibition – to build relationships and market its upcoming products to investors, governments, and healthcare providers.
Financially, Co-Dx’s balance sheet got a modest boost recently. Just last month (Sept 18), the company raised $3.8 million in gross proceeds through a direct offering of 9.6 million shares at $0.40 each [57]. While highly dilutive (increasing the share count by roughly 20%), that financing was done at-the-market, meaning no steep discount was applied – a sign that some institutional investors were willing to fund Co-Dx near its market price. The cash is earmarked for working capital and general corporate purposes [58], which likely include finishing development of the PCR Home/Pro platform and preparing for its commercialization. Prior to the stock’s recent jump, Co-Diagnostics’ market capitalization was only around $18 million [59]. Now, after Monday’s rally, it sits closer to an estimated $50–60 million, still a very small company. This micro-cap status means the stock can be volatile, but also that successful execution (for instance, meaningful revenue from CoMira or FDA approval of the new platform) could have an outsized impact on valuation.
Looking ahead, investors will be watching a few key items:
- Earnings Update: Co-Diagnostics is expected to report Q3 2025 results in early November (around Nov 5–6 [60]). Although no big jump in revenue is anticipated yet, management’s commentary could provide clues on the timeline for the PCR platform’s launch and any early sales of other products (e.g. its Logix Smart test kits still being sold for research or non-U.S. markets).
- Regulatory Milestones: Any progress with the FDA or other regulators on approving Co-Dx’s new tests will be crucial. Even a limited Emergency Use Authorization or foreign regulatory clearance could validate the platform. Likewise, developments in Saudi regulatory approval through the CoMira venture will be important to open that market.
- Execution of CoMira JV: Over the coming quarters, investors will look for concrete steps by CoMira – such as setting up a manufacturing facility in Saudi Arabia, securing Saudi government support or purchase orders, and beginning the regulatory registration in the 19 target countries. Success in these steps would turn the JV from a announced plan into a revenue-generating operation.
- Cash Burn and Capital Needs: With roughly $3–4 million freshly raised and historically low revenues, Co-Dx will need to manage its cash carefully. The company may still require additional funding if product launches are delayed. However, the recent surge in stock price potentially makes future fundraising less dilutive (a positive for current shareholders).
In the bigger picture, Co-Diagnostics, Inc. now has a new narrative: no longer just a struggling COVID test company, but a diagnostics innovator making inroads in emerging markets. The Saudi Arabia joint venture is a pivotal development that brings both credibility and expanded scope to Co-Dx’s mission of improving global health through molecular diagnostics. “This partnership represents a compelling model for combining international innovation with strong local leadership,” said Ihssan Rjoob, CEO of Arabian Eagle, emphasizing how CoMira will leverage Co-Dx’s tech with on-the-ground expertise [61].
For public investors, CODX remains a speculative bet – the stock’s sharp swings this year (down 70% then up 200% overnight) reflect a business at an inflection point with plenty of uncertainties. Yet the recent developments have clearly tilted the outlook toward optimism. Analysts and industry observers will be keenly following whether Co-Diagnostics can convert this momentum into tangible growth. If the company delivers on its promises – rolling out its PCR platform and expanding in high-demand markets – the current share price could indeed be “just the beginning,” as some bulls hope. Conversely, challenges in execution or regulatory delays could temper the market’s excitement just as quickly as it arrived.
Bottom Line: Co-Diagnostics’ stock is making headlines for its explosive rally, driven by the Middle East JV that significantly expands the company’s horizons. With fresh investor attention, supportive analysts, and a bold international strategy, CODX has entered a new chapter. Now the company must prove that its innovative diagnostics technology can achieve real-world uptake. The coming months will reveal whether this week’s stock surge was an overreaction or a justified re-rating for a biotech underdog with global ambitions. Investors should buckle up – as Co-Dx’s story unfolds, volatility is likely to remain high, but so too is the potential for further news-fueled moves.
Sources: Co-Diagnostics press releases [62] [63] [64]; Benzinga Market Update [65]; AsiaNet News via MENAFN [66] [67]; Investing.com [68] [69]; Nasdaq/Fintel analyst data [70]; Benzinga analyst consensus [71]; Simply Wall St/Yahoo Finance [72]; TickerNerd forecasts [73]; Stock Titan news [74]; Yahoo Finance historical prices [75].
References
1. www.benzinga.com, 2. finance.yahoo.com, 3. www.nasdaq.com, 4. ir.co-dx.com, 5. ir.co-dx.com, 6. ir.co-dx.com, 7. menafn.com, 8. tickernerd.com, 9. www.benzinga.com, 10. tickernerd.com, 11. ir.co-dx.com, 12. ca.investing.com, 13. ir.co-dx.com, 14. www.prnewswire.com, 15. www.benzinga.com, 16. menafn.com, 17. finance.yahoo.com, 18. www.nasdaq.com, 19. tickernerd.com, 20. menafn.com, 21. www.benzinga.com, 22. ir.co-dx.com, 23. ir.co-dx.com, 24. ir.co-dx.com, 25. ir.co-dx.com, 26. ir.co-dx.com, 27. ir.co-dx.com, 28. ir.co-dx.com, 29. www.investing.com, 30. www.investing.com, 31. ir.co-dx.com, 32. menafn.com, 33. menafn.com, 34. ir.co-dx.com, 35. www.prnewswire.com, 36. www.stocktitan.net, 37. ir.co-dx.com, 38. ir.co-dx.com, 39. tickernerd.com, 40. tickernerd.com, 41. tickernerd.com, 42. www.benzinga.com, 43. www.benzinga.com, 44. www.nasdaq.com, 45. tickernerd.com, 46. tickernerd.com, 47. ts2.tech, 48. finance.yahoo.com, 49. ca.investing.com, 50. ca.investing.com, 51. ir.co-dx.com, 52. ir.co-dx.com, 53. ir.co-dx.com, 54. www.investing.com, 55. ir.co-dx.com, 56. www.stocktitan.net, 57. www.prnewswire.com, 58. www.prnewswire.com, 59. tickernerd.com, 60. public.com, 61. ir.co-dx.com, 62. ir.co-dx.com, 63. ir.co-dx.com, 64. www.prnewswire.com, 65. www.benzinga.com, 66. menafn.com, 67. menafn.com, 68. www.investing.com, 69. www.investing.com, 70. www.nasdaq.com, 71. www.benzinga.com, 72. ca.investing.com, 73. tickernerd.com, 74. www.stocktitan.net, 75. www.nasdaq.com
